Validation of manufacturing processes, handling of deviations, and laboratory operations are the top three areas that FDA investigators scrutinize during GMP inspections due to which FDA 483 warning letters are issued, according to a senior regulatory operations officer with the Center for Drug Evaluation and Research (CDER).
Select all the resources you’re interested in downloading
In this Q&A session, MasterControl copywriter and editor, Cindy Fazzi, interviews Kristen Evans, senior regulatory operations officer at the Office of Compliance of the FDA's Center for Drug Evaluation and Research (CDER). They discuss the following reasons due to which FDA 483 warning letters are issued:
With more than a decade of experience in the rigorous FDA environments, MasterControl has developed an integrated software solution that combines industry best practices with the flexibility to meet every customer's unique needs and saves from being claimed for FDA 483 warning letters.
The MasterControl quality and compliance management suite consists of configurable, easy-to-use, and connected applications for automating, streamlining, and effectively managing document control, change control, training control, audits, corrective/preventive action (CAPA), customer complaints, and other documents. It is a form based business processes under a single Web-based platform which electronically can manage all processes which helps in ultimately avoid FDA 483 warning letters. Hundreds of companies worldwide rely on MasterControl to facilitate compliance with FDA regulations (e.g., 21 CFR Parts 11, 210-211, 820, 606).